Jazz Pharmaceuticals (JAZZ) Total Debt (2010 - 2026)

Jazz Pharmaceuticals' Total Debt history runs 17 years deep, the most recent figure standing at $5.4 billion for Q1 2026.

• In Q1 2026, Total Debt fell 0.81% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at $5.4 billion (down 0.81% YoY), while the FY2025 annual figure was $6.4 billion, up 4.58% from the prior year.
• Total Debt for Q1 2026 stood at $5.4 billion, down from $6.4 billion in the prior quarter.
• The five-year high for Total Debt was $6.4 billion in Q2 2025, with the low at $5.4 billion in Q1 2026.
• The 5-year median for Total Debt is $5.8 billion (2022), against an average of $5.9 billion.
• Peak annual rise in Total Debt reached 186.63% in 2022, while the deepest fall reached 13.38% in 2022.
• Jazz Pharmaceuticals' Total Debt stood at $5.7 billion in 2022, then dropped by 0.2% to $5.7 billion in 2023, then gained by 6.93% to $6.1 billion in 2024, then grew by 4.58% to $6.4 billion in 2025, then declined by 16.18% to $5.4 billion in 2026.
• Business Quant data shows JAZZ's Total Debt at $5.4 billion in Q1 2026, $6.4 billion in Q4 2025, and $6.4 billion in Q3 2025.